RxDoctor Payments Data

Bruce Tjaden, MD

Vascular Surgery · Moorestown, NJNPI 1477846046

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (37.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Penumbra, Inc. at 55.6% of the total. Reporting peaked in 2023 at $15,458 and has fallen 86.0% since, to $2,169 in 2025.

$24,681in general payments, 2019–2025

Across 146 payments — averaging $169.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$14K
  • W. L. Gore & Associates, Inc.$3K
  • Endologix LLC$2K
  • Medtronic$2K
  • Inari Medical, Inc.$769
  • Davol Inc.$750
  • plus $3K from 18 others

What the payments were for

  • Speaking & faculty fees$6,75027%
  • Travel & lodging$9,27838%
  • Food & beverage$8,65335%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,681 in reported general payments places this provider in the 85th percentile of 182 vascular surgery providers in New Jersey.

See all vascular surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$151,503
Medicare patients
213
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate27$86

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Moorestown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →